TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...